Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

Presentation ACC 2017

Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis

Presenter: Stephen J Nicholls

March 20, 2017

Presentation ACC 2017

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Presenter: Jeff Weitz

March 20, 2017

Presentation ACC 2017

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Presenter: Robert Giugliano

March 19, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

L.A. McKeown

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

Presentation ACC 2017

ORION-1: Primary Efficacy & Safety Outcomes

Presenter: Kausik K. Ray

March 17, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Presentation ACC 2017

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Presenter: Marc Sabatine

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News ACC 2017

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

Shelley Wood

March 09, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

Advertisement

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

ORION-1: Primary Efficacy & Safety Outcomes

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content